Abstract
We assessed the broadly used, off-label combination of sofosbuvir, daclatasvir, simeprevir, and ribavirin in direct-acting antiviral-experienced patients, as recommended in current guidelines despite scarce data. After 24 weeks' treatment, sustained virological response 12 weeks after the end of treatment was achieved in 6 patients (60%). Two cirrhotic patients relapsed and 2 discontinued treatment due to serious adverse events.
Keywords:
chronic hepatitis C; resistance; resistance-associated substitutions.; retreatment; sustained virological response.
© The Author 2017. Published by Oxford University Press for the Infectious Diseases Society of America. All rights reserved. For permissions, e-mail: [email protected].
MeSH terms
-
Antiviral Agents / administration & dosage
-
Antiviral Agents / adverse effects
-
Antiviral Agents / therapeutic use*
-
Carbamates
-
Drug Resistance, Viral / genetics
-
Drug Therapy, Combination
-
Female
-
Genotype
-
Hepacivirus / genetics
-
Hepatitis C / drug therapy*
-
Hepatitis C, Chronic / drug therapy*
-
Humans
-
Imidazoles / administration & dosage
-
Imidazoles / adverse effects
-
Imidazoles / therapeutic use
-
Male
-
Middle Aged
-
Pyrrolidines
-
Recurrence
-
Ribavirin / administration & dosage
-
Ribavirin / adverse effects
-
Ribavirin / therapeutic use
-
Simeprevir / administration & dosage
-
Simeprevir / adverse effects
-
Simeprevir / therapeutic use
-
Sofosbuvir / administration & dosage
-
Sofosbuvir / adverse effects
-
Sofosbuvir / therapeutic use
-
Sustained Virologic Response
-
Valine / analogs & derivatives
Substances
-
Antiviral Agents
-
Carbamates
-
Imidazoles
-
Pyrrolidines
-
Ribavirin
-
Simeprevir
-
Valine
-
daclatasvir
-
Sofosbuvir